Characteristics | Progression-free survival | Overall survival | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||
HR | 95% CI | aHR | 95% CI | P | HR | 95% CI | aHR | 95% CI | P | |
Age at initial diagnosis, years | ||||||||||
≥55 vs. <55 | 0.83 | 0.57–1.19 | 0.75 | 0.51–1.08 | 0.122 | 0.96 | 0.51–1.78 | |||
Histologic type | ||||||||||
Non-HGSC vs. HGSC | 1.10 | 0.64–1.90 | 0.80 | 0.29–2.26 | ||||||
FIGO stage | ||||||||||
IV vs. I-III | 1.15 | 0.77–1.71 | 0.81 | 0.53–1.22 | 0.308 | 0.98 | 0.48–2.00 | 0.78 | 0.37–1.66 | 0.515 |
Primary treatment strategy | ||||||||||
NAC vs. PDS | 0.92 | 0.60–1.39 | 2.28 | 1.20–4.34 | ||||||
Results of initial debulking surgery | ||||||||||
Residual tumor vs. CGR | 1.16 | 0.81–1.66 | 1.26 | 0.68–2.36 | ||||||
Platinum-free interval, months | ||||||||||
≥12 vs. 6–12 | 0.46 | 0.31–0.66 | 0.42 | 0.29–0.63 | <0.001 | 0.36 | 0.19–0.67 | 0.37 | 0.19–0.70 | 0.003 |
CA-125 at 1st recurrence, IU/mL | ||||||||||
≥90 vs. <90 | 1.76 | 1.22–2.53 | 2.21 | 1.50–3.25 | <0.001 | 1.92 | 1.02–3.60 | 1.90 | 1.00–3.60 | 0.050 |
Secondary debulking surgery | ||||||||||
Yes vs. No | 0.67 | 0.37–1.22 | 0.88 | 0.27–2.88 | ||||||
Residual tumor on CT after #6 | ||||||||||
≥1 cm vs. <1 cm | 1.09 | 0.76–1.56 | 1.20 | 0.83–1.74 | 0.326 | 2.01 | 1.04–3.90 | 2.38 | 1.20–4.71 | 0.013 |
CA-125 after #6, IU/mL | ||||||||||
≥12.5 vs. <12.5 | 1.50 | 1.04–2.15 | 1.47 | 0.79–2.73 | ||||||
Maintenance therapy | ||||||||||
Yes vs. No | 0.50 | 0.32–0.76 | 0.44 | 0.28–0.69 | <0.001 | 0.67 | 0.30–1.53 | 0.65 | 0.28–1.52 | 0.317 |
Extended chemotherapy | ||||||||||
Yes vs. No | 1.61 | 1.11–2.34 | 1.25 | 0.84–1.85 | 0.279 | 1.32 | 0.71–2.44 | 1.36 | 0.72–2.56 | 0.342 |